Kymriah, approved recently by the F.D.A., with a $475,000 price tag, is first of a coming wave of treatments whose expected prices have alarmed economists, scientists and insurers.
Published: September 11, 2017 at 02:00AM
from NYT Health https://ift.tt/2jinaom